773 - Impact of lymph node level assessment for survival on time to relapse in biliary tract cancers

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Hepatobiliary Cancers
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Joaquina Martinez-Galan
Authors J. Martinez-Galan1, P. Ballesteros2, B. Gonzalez-Astorga3, J.A. Ortega3, A. González-Vicente3, J. Soberino3, C. González-Rivas2, J. Ruíz Vozmediano3, T. Villegas4, J.R. Delgado3
  • 1Medical Oncology, Hospital Universitario Virgen de las Nieves, 18011 - Granada/ES
  • 2Medical Oncology Department, Hospital Universitario de Ceuta, 51003 - Ceuta/ES
  • 3Medical Oncology Department, Hospital Universitario Virgen de las Nieves, 18011 - Granada/ES
  • 4Surgical Department, Hospital Virgen de las Nieves, 18011 - Granada/ES



Biliary tract cancers (BTCs) are relatively rare neoplasms encompass both cholangiocarcinoma (CC). The role of routine lymphadenectomy at the time of surgical resection remains poorly defined. We sought to identify factors associated with outcome following and examine the impact of lymph node (LN) assessment on survival.


43 patients who underwent curative intent surgery between 2000-2010 were identified from a database. We calculated prognostic factors and impact lymph node (LN) assessment for survival.


A total of 43 patients were identified with no metastatic BTCs. The median age was 65 years (29–82 years); performance status of 0 in 33/43 (76%); PS1 in 8/43 (19%) and PS2 in 2/43 (5%) pts. A histological diagnosis of adenocarcinoma was confirmed in 100%. Surgical resection was performed in all patients. After resection 42% (18/43) had positive nodes.Adjuvant chemotherapy had 31/43(72%), preferred with gemcitabine and a median number of cycles 6. Grade 3 or 4 toxicities rarely occurred. During median follow-up of 6.6 years tumor recurrence or metastatic disease occurred in 63% with median survival global were 2 years and 1.5 years for disease free survival.For stage T, the median survival global rates were 58 months (95% CI 44.6-71.3) for T1-T2 and 35 months (95% CI 23.3-46.8) for T3-T4 (p = 0.015) and for median recidive-free survival were 23 months (95% CI 11.8-34) for T1-T2 and 14 months (95% CI 6.5-21) for T3-T4 (p = 0.05). For N stage, the median survival global were 58 months (95% CI 50.5-65.4) for negative nodes and 26 months (95% CI 3.7-48.2) for positive nodes (p = 0.003) and for median recidive-free survival were 55 months (95% CI 31.7-57.5) for negative nodes and 10 months (95% CI 6.8-13) for positive nodes (p = 0.006). The patients who had nodal affectation in hepatic hilio had better recidive-free survival that those patients who had nodal affectation in celiac trunk p < 0.05.


This represents a biliary cancer cohort with survival benchmarks obtained in the modern era of multidisciplinary care. Surgical resection and adjuvant chemotherapy offers the optimal treatment outcome in patients with ICC. From our results depth of tumor invasion (T), the presence the lymph node metastases (N) and level nosal affections are the strongest predictors of relapse and survival


All authors have declared no conflicts of interest.